Risk and Volatility
NKGen Biotech has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500.
Valuation and Earnings
This table compares NKGen Biotech and SQZ Biotechnologies”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NKGen Biotech | N/A | N/A | -$82.94 million | ($1.51) | -0.04 |
| SQZ Biotechnologies | $18.16 million | 0.04 | -$79.46 million | ($2.61) | -0.01 |
Insider & Institutional Ownership
76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares NKGen Biotech and SQZ Biotechnologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NKGen Biotech | N/A | N/A | -479.36% |
| SQZ Biotechnologies | -369.96% | -119.83% | -59.90% |
Summary
SQZ Biotechnologies beats NKGen Biotech on 6 of the 10 factors compared between the two stocks.
About NKGen Biotech
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
About SQZ Biotechnologies
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for NKGen Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NKGen Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
